Although both CD4+ and CD8+ T cells are clearly required to generate long-lasting anti-tumor immunity induced by s.c. vaccination with interleukin 2 (IL-2)-transfected, irradiated M-3 clone murine melanoma cells, some controversy continues about the site and mode of T-cell activation in this system. Macrophages, granulocytes, and natural killer cells infiltrate the vaccination site early after injection into either syngeneic euthymic DBA/2 mice or athymic nude mice and eliminate the inoculum within 48 hr. We could not find T cells at the vaccination site, which argues against the concept that T-cell priming by the IL-2-secreting cancer cells occurs directly at that location. However, reverse transcription-PCR revealed transcripts indicative of T-cell activation and expansion in the draining lymph nodes of mice immunized with the IL-2-secreting vaccine but not in mice vaccinated with untransfected, irradiated M-3 cells. We therefore propose that the antigen-presenting cells, which invade the vaccination site, process tumor-derived antigens and, subsequently, initiate priming of tumor-specific T lymphocytes in lymphoid organs. These findings suggest a three-stage process for the generation of effector T cells after vaccination with IL-2-secreting tumor cells: (i) tumor-antigen uptake and processing at the site of injection by antigen-presenting cells,
circulation of activated T cells that either perform or initiate effector mechanisms leading to tumor cell destruction.
We have generated a cancer vaccine by transfecting the melanoma Cloudman S91 clone M-3 (referred to as M-3) with a murine interleukin 2 (IL-2) gene driven by a cytomegalovirus promoter/enhancer and examined its influence on the fate of subsequently injected live M-3 cells in syngeneic DBA/2 hosts (1, 2). For gene delivery we used the adenovirus-enhanced receptor-mediated gene transferrinfection technique (3) . This technique is exceptionally efficient in transiently transfecting a large proportion of exposed cells and can be used for a broad range of cell types. ,IL-2 has been used successfully in other cancer treatment models-administered i.v. or locally (4) , secreted by admixed cells (5) , and also delivered by transfected tumor cells as a "vaccine" (6) (7) (8) . We find that two consecutive vaccinations with i05 transfected, irradiated M-3 cells secreting 1-3 x 103 units of IL-2 per 105 cells and 24 hr in vitro protect animals from tumor development by a challenge with 105 or 3 x 105 wild-type M-3 cells 1 week later (9) and that immunized animals also reject a tumor challenge after several months (1) . As 
shown by T-cell transfer experiments, this
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systemic tumor-specific protection critically depends on both CD4+ and CD8+ T cells. Correspondingly, no long-lasting systemic protection could be achieved in athymic nude mice. However, T cells are apparently not required for eliminating viable IL-2-secreting M-3 melanoma cells because these cells were effectively rejected in athymic nude mice (1) .
A conceptual dilemma arises when one attempts to apply to the M-3 system the theory that the mechanism of action of IL-2-based cancer vaccines is helper T cell-independent-i.e., through direct activation of CD8+ T cells by IL-2-transfected tumor cells. For instance, it is unclear how tumor-reactive CD4+ cells are activated and clonally selected because M-3 tumor cells, while weakly reactive with anti-major histocompatibility complex class I antibodies, are consistently major histocompatibility complex class II negative both in vivo and in vitro (1) . Further, how naive T cells make contact with the tumor antigens of the IL-2-secreting vaccine implanted s.c. is not understood because naive T cells do not appear in sizable quantities in nonlymphoid tissues (10, 11) .
Here, we investigate the fate of the vaccine cells, their interaction with the immune system, and the location and course of events of T-cell activation and expansion in response to IL-2-secreting vaccines. tories, Houston), treated with RNase-free DNase I (Boehringer Mannheim) to avoid cross-reactivity with genomic DNA, and reverse-transcribed with oligo(dT) primers (12) . Cytokine messages were then amplified by PCR with specific primers purchased from Clontech, except for the following: CD69, 5'-CCTTGGGCTGTGTTAATAGTGG-3' and 5'-AACTT-TCCTGTGGTGCTATGGC-3'; granzyme B, 5'-GGCAAA-TACTCAAACACGCTACAAG-3' and 5'-GCAATCC-TG-GACTCAGCTCTAGG-3'; CTLA-4, 5 '-GGTCTCTGC-TGTTTCTTTGAGCAAG-3' and 5'-GCTATATCCTTAT-GCTGCTTCCAAGTG-3'; f3-actin, 5'-GTGGGCCGCTCT-AGGCACCA-3' and 5 '-CGGTTG GCCTTAGGGTTC-AGGGGGG-3'. Amplified DNA products were visualized on a 2% agarose gel.
MATERIAL AND METHODS
Immunohistology. Sections were prepared as described (1) 
RESULTS
Rapid Elimination of Tumor Vaccines and Secondary Cytokine Responses in Vivo. The persistence of the transfected IL-2 plasmid was used as a measure of survival of the cell vaccine at the vaccination site. Groups of DBA/2 mice (three animals each) were injected s.c. with 3 x 105 M-3 cells that had been transfected with the IL-2 expression vector and then irradiated. Animals were sacrificed 1, 2, or 5 days thereafter. Competitive PCR analysis of the injection sites showed a rapid elimination of the transfected IL-2 plasmid (Fig. 1) . Although easily detectable on day 1 and in smaller quantities on day 2, the IL-2 sequence could no longer be amplified on day 5. This result contrasts with the situation in vitro where the IL-2 transgene can be detected for at least 15 days (Fig. 1) .
The rapid kinetics of vaccine elimination prompted us to start analysis of mRNA recovered from vaccination sites 6 hr after injection. mRNAs of cytokines IL-1, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor a, transforming growth factor (TGF) B, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interferon -y (IFN--y) and of T-cell activation markers IL-2 receptor a (IL-2Ra) chain (CD25), CD69, granzyme B (CTLA-1) and CTLA-4 were determined by semiquantitative RT-PCR. In addition, amplification of f3-actin mRNA was chosen to gauge efficiency in all experiments. IL-2-secreting, irradiated M-3 cells induce enhanced signals for IL-1, IL-6, IL-10, and GM-CSF mRNA in vivo. Thus, secretion of IL-2 at appropriate levels initiates a cascade of into each of nine DBA/2 mice. After 1, 2, and 5 days, immunization sites from three mice were excised, and total DNA was purified. Copies (103) of the internal control plasmid were added for semiquantitative analysis for persistence of IL-2 plasmid DNA. secondary cytokines at the vaccination site (Fig. 2) . Native tumor cells produce mRNAs for TGF-f3 in vitro. At the vaccination site in vivo, irradiated, nontransfected M-3 melanoma cells (and surrounding tissue) also display a TGF-f3 response together with weak IL-10 and GM-CSF signals. However, TGF-,B mRNA was not detected at the immunization site of the IL-2-secreting vaccine, indicating a downregulation of this mRNA in vivo probably as a consequence of IL-2 secretion. Among the activation markers tested, only granzyme B mRNA, a transcript also found in natural killer cells, was faintly detectable at the injection site of IL-2-secreting vaccines (see Fig. SC ) but not at sites of irradiatedonly cells. Other T-cell markers such as IL-4, IL-2Ra, or CTLA-4 transcripts were not in evidence; hence there is no indication of T-cell priming at the injection site. At 6 hr after injection of IL-2-expressing M-3 cells, the cytokine mRNA pattern in nude mice was identical.to that of immunocompetent DBA/2 host (Fig. 2) . Therefore, the mRNAs that were induced or enhanced by the IL-2 vaccination procedure-i.e., IL-1, IL-6, IL-10, and GM-CSF-are unlikely to be of T-cell origin but rather reflect the inflammatory reaction at the vaccination site.
Immunohistology Fig. 3 d and e). Staining with granulocyte-specific antibody GR-1 revealed accelerated infiltration by granulocytes at 24 hr as compared with F4/80 antibody-stained cells (Fig. 3g) . At 48 hr after immunization the granulocyte influx was very similar in numbers to that of macrophage-like cell types (Fig. 3h) . Antiasialo-GM1 antiserum, which identifies natural killer cells, showed less of these cells in tissues surrounding the vaccine at 24 hr, and even fewer natural killer cells were seen surrounding nontransfected, irradiated M-3 cells (Fig. 3 c andf) . In neither vaccine were T cells (CD3+, CD4+, or CD8+) or B cells (CD45 receptor/B220) detectable (data not shown). Athymic nude mice readily reject live IL-2-secreting M-3 cells (1). The composition of the infiltrating cells in nude mice qualitatively matched the cells infiltrating the vaccine in immunocompetent mice; macrophages and granulocytes accumulated rapidly in IL-2-secreting inocula ( Fig. 3 k and 1 ), whereas only very few of these cells were detectable after injection of irradiated-only M-3 cells (Fig. 3 n and o) . Staining with anti-asialo-GM1 antiserum essentially mirrored the situation seen in DBA/2 mice (Fig. 3 m and p) . The major difference between athymic and euthymic mice was the magnitude of the granulocyte response, in that the IL-2-expressing inoculum induced -3-fold influx in nude mice compared with DBA/2 mice at 24 hr after injection (compare Fig. 3 g and 1) . As in the immunocompetent host, nude mice eliminated IL-2-producing tumor masses at 48 hr (data not shown). This fact is evidence that IL-2-secreting tumor cell masses can be rejected in a system devoid of T cells, presumably by a nonspecific immune response based on natural killer cells, macrophages, and granulocytes.
Ingestion of Tumor Cells by Macrophages at the Vaccination Site. The simplest interpretation of Figs. 1 and 3b is that the invading macrophage-like cells ingest the tumor cells and tumor cell debris and thus quickly destroy the inoculum of IL-2-secreting tumor cells in both DBA/2 and nude mice. That this is, indeed, the case can be deduced from experiments in which we preloaded IL-2-producing M-3 cells in vitro with latex beads (0.5 ,tm) and detected the transfer of these beads into macrophages as shown by electron microscopy (Fig. 4) . This result suggests that macrophages also ingest M-3 tumor antigens and that these altered macrophages may act as antigen- (Fig. S A and B) . Strong signals for IL-2, IL-4, and IFN-y mRNA together with the appearance of CD69, granzyme B (CTLA-1), and CTLA-4 mRNA, indicating activation and expansion of T cells, were detected in mice inoculated with the IL-2-secreting vaccine. Similar patterns of amplified transcripts were already obtained after a single vaccination but were enhanced after the second vaccination (Fig. SB) . By contrast, in animals immunized with untrans- fected irradiated M-3 cells, only the CD69 amplification product could be detected (Fig. SA) , and the same result was obtained from naive controls (data not shown). Note that the above transcripts could not be detected at the IL-2-secreting vaccination site, except for the expected strong signal for IL-2 and a very weak signal for granzyme B transcripts (Fig. SC) , which might be caused by the infiltrating sparse natural killer cells detected in Fig. 3c .
DISCUSSION
An unexpected result of the above immunohistological investigation was the great similarity of cell types infiltrating the vaccination sites of both immunocompetent and nude mice. Interestingly, a similar situation pertains at the challenge site in euthymic DBA/2 mice, although here participation of T cells was clearly demonstrated (1 (2, 9) .
The amount of IL-2 secreted by the vaccine is critical for the generation of antitumor immunity, with 1000-3000 units of IL-2 per mouse yielding the optimal vaccination effect (9), whereas lower as well as higher values are much less effective. We see the contribution of IL-2 not so much in the preferential recruitment of specific cell subsets but rather in the augmentation of the function of the cell types-particularly macrophage-like cells, which invade the inoculum. IL-2 can directly augment antitumor activity of monocytes (13) and also contributes to the induction of other macrophage functions (14) . In addition, other secondary mediators, such as GM-CSF (Fig.  2) , the release of which is triggered by IL-2 may also substantially contribute to macrophage activation (15) . Granulocytes most likely represent a population that may not depend critically on IL-2 per se because (i) IL-2 is not a major granulocyte regulator, and (ii) the granulocyte infiltrate has also been recorded in granulocyte colony-stimulating factor- (16) and in IL-4-secreting systems (17, 18) , although with a predominance of eosinophils in the latter case. We propose that granulocytes may actually appear not as a cause but rather as a result of tumor destruction by the macrophage-like cells. For the IL-2-secreting vaccine this view is also supported by the dynamics of appearance of these cells-namely, that the influx peak of macrophages precedes that of granulocytes (unpublished results). However, with the many potent proinflammatory, chemotactic factors they release, granulocytes may actually amplify the tumor destruction, promoting the explosive cellular accumulation that we observe.
Massive infiltration with inflammatory cells was previously recorded for inocula of granulocyte colony-stimulating factorexpressing adenocarcinoma C-26 (16) systems (1) . CD4+ cells clearly cannot be activated directly by the M-3 cells, which express only low levels of major histocompatibility complex class I but no class II (1). Theoretically, M-3 cells might react with CD8+ T cells, which, however, are absent from the inoculum. It may, of course, be argued that the transition time of CD8+ cells in the cytokine-producing implant is very short, making the detection of the cells more difficult. This argument is, however, offset by the need of a great many contacts because only a tiny proportion of the naive CD8+ cells would be expected to react with the tumor antigen, thus requiring a large flux of cells through the inoculum, necessary for activation and clonal selection of CD8+ cells.
These considerations suggest an alternative scheme for the establishment of T-cell activation, which is based on tumor antigens being processed by antigen-presenting cells that transfer them to the lymph node, where T-cell priming then occurs. That this hypothesis is a likely alternative is supported by our findings that (i) macrophage-like cells ingest tumor cells at the vaccination site, (ii) the draining lymph nodes are extensively enlarged, and (iii) mRNAs diagnostic of activated T lymphocytes (19) are detected in this compartment. Thus, mRNAs for the IL-2Ra, IL-2, IL-4, and IFN-y, which are indicative of T-cell activation and expansion, become detectable only after administration of an IL-2-secreting vaccine but cannot be amplified after injection of irradiated-only M-3 cells. mRNAs for granzyme B in combination with mRNA for CTLA-4 are diagnostic for activated T cells with prospective cytotoxic function. CD69 is also anticipated soon after T-cell activation, but this marker is expressed by other activated hematopoietic cells (20) . We suggest that it is in the lymph node compartment that both CD4+ and CD8+ cells are programmed by antigenpresenting cells, which have passed through the vaccination site. A similar hypothesis has also been posited from theoretical consideration by Gilboa's group (8) . The alternative they considered-namely, that IL-2-producing tumor cells might migrate into the lymph node and activate T cells at this location-is not supported by our experiments in the M-3 system. Neither tyrosinase transcripts (Michael Buschle, personal communication), easily detectable in M-3 cells, nor IL-2 transgene sequences originating from injected tumor cells could be amplified by high-sensitivity PCR from draining lymph node cells (21) . However, our postulate agrees with recent work by Huang et al (22) , who concluded from elegantly designed mouse bone marrow-transplantation experiments that bone marrow-derived antigen-presenting cells are instrumental for the generation of systemic antitumor immunity.
Note Added in Proof. In recent experiments we found that mice that had their lymph nodes depleted of naive T cells by in vivo antibody treatment were unable to develop protective anti-tumor immunity. Thus, de novo priming of naive T cells in the lymph nodes is indispensable for a successful immunization.
